Genprex (GNPX) Non-Current Assets (2016 - 2026)
Genprex (GNPX) posted quarterly Non-Current Assets of $1.5 million for Q1 2026, down 18.57% year-over-year from $1.8 million in Q1 2025, and down 16.59% quarter-over-quarter from $1.8 million in Q4 2025.
Genprex (GNPX) Non-Current Assets (2016 - 2026) Analysis & Trends
Genprex's Non-Current Assets history runs 11 years deep, the most recent figure standing at $1.5 million for Q1 2026.
- In Q1 2026, Non-Current Assets fell 18.57% year-over-year to $1.5 million; the TTM figure through Mar 2026 stood at $6.9 million (down 14.44% YoY), while the FY2025 annual figure was $1.8 million, down 11.95% from the prior year.
- Non-Current Assets for Q1 2026 stood at $1.5 million, down from $1.8 million in the prior quarter.
- The five-year high for Non-Current Assets was $3.8 million in Q3 2023, with the low at $1.5 million in Q1 2026.
- The 5-year median for Non-Current Assets is $3.1 million (2023), against an average of $2.8 million.
- The sharpest annual moves came in 2022 and 2024: Non-Current Assets soared 462.64% in 2022, then sank 47.45% in 2024.
- Genprex's Non-Current Assets stood at $3.6 million in 2022, then decreased by 13.1% to $3.1 million in 2023, then sank by 34.79% to $2.0 million in 2024, then slipped by 11.95% to $1.8 million in 2025, then dropped by 16.59% to $1.5 million in 2026.
- Business Quant data shows GNPX's Non-Current Assets at $1.5 million in Q1 2026, $1.8 million in Q4 2025, and $1.8 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 140.39 Bn | 132.54 Bn | 2.84 Bn | 14.88 Bn |
| 2 | Regeneron Pharmaceuticals | 86.47 Bn | 78.47 Bn | 3.93 Bn | 23.28 Bn |
| 3 | Argenx Se | 65.25 Bn | 60.07 Bn | 1.37 Bn | 1.96 Bn |
| 4 | Moderna | 61.79 Bn | 56.66 Bn | 52.00 Mn | 5.15 Bn |
| 5 | BeOne Medicines | 42.27 Bn | 37.17 Bn | 1.53 Bn | 1.96 Bn |
| 6 | Alnylam Pharmaceuticals | 31.17 Bn | 27.86 Bn | 992.69 Mn | 938.60 Mn |
| 7 | BioNTech SE | 28.61 Bn | 10.22 Bn | 668.28 Mn | 6.80 Bn |
| 8 | Insmed | 27.44 Bn | 26.28 Bn | 358.27 Mn | 468.65 Mn |
| 9 | Royalty Pharma | 27.30 Bn | 26.46 Bn | - | 18.06 Bn |
| 10 | Genprex | 1.90 Mn | -13.26 Mn | - | 1.29 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 1.50 Mn |
| Dec 31, 2025 | 1.80 Mn |
| Sep 30, 2025 | 1.85 Mn |
| Jun 30, 2025 | 1.77 Mn |
| Mar 31, 2025 | 1.85 Mn |
| Dec 31, 2024 | 2.05 Mn |
| Sep 30, 2024 | 1.99 Mn |
| Jun 30, 2024 | 2.21 Mn |
| Mar 31, 2024 | 3.34 Mn |
| Dec 31, 2023 | 3.14 Mn |
| Sep 30, 2023 | 3.79 Mn |
| Jun 30, 2023 | 3.55 Mn |
| Mar 31, 2023 | 3.38 Mn |
| Dec 31, 2022 | 3.61 Mn |
| Sep 30, 2022 | 3.64 Mn |
| Jun 30, 2022 | 3.66 Mn |
| Mar 31, 2022 | 3.71 Mn |
| Dec 31, 2021 | 3.72 Mn |
| Sep 30, 2021 | 682,443.00 |
| Jun 30, 2021 | 669,908.00 |